Table 1. Demographic and clinical characteristics of patients hospitalized with COVID-19 who received regdanvimab from September through December 2021.
| Characteristics | Number (n = 374) | |
|---|---|---|
| Age (years) | 65 (53 - 75) | |
| Age ≥60 years | 245 (65.5) | |
| Female | 196 (52.4) | |
| Body mass index ≥30 kg/m2 | 43 (11.5) | |
| Medical comorbidities | 299 (79.9) | |
| Cardiovascular disease or hypertension | 198 (52.9) | |
| Diabetes mellitus | 95 (25.4) | |
| Cancer | 40 (10.7) | |
| Chronic lung disease | 34 (9.1) | |
| Immunocompromised condition | 17 (4.5) | |
| Chronic liver disease | 6 (1.6) | |
| Neurodevelopmental disorder | 6 (1.6) | |
| Chronic kidney disease | 12 (3.2) | |
| Other | 37 (17.9) | |
| Number of risk factors | ||
| 0 | 52 (13.9) | |
| 1 | 66 (17.6) | |
| 2 | 126 (33.7) | |
| 3 | 88 (23.5) | |
| 4 | 35 (9.4) | |
| 5 | 7 (1.9) | |
| Severity of disease [15] | ||
| Asymptomatic | 26 (7.0) | |
| Mild | 172 (46.0) | |
| Moderate | 176 (47.0) | |
| Days from symptom onset to admission | 3 (2 - 5) | |
| Days from symptom onset to regdanvimab infusion | 4 (2 - 6) | |
| Days from admission to regdanvimab infusion | 1 (0 - 1) | |
| Duration of hospitalization (days) | 8 (6 - 9) | |
| Vaccination statusa | ||
| Fully vaccinated | 226 (60.4) | |
| Partially vaccinated | 39 (10.5) | |
| Unvaccinated | 109 (29.1) | |
| SpO2 (%) on the day of regdanvimab administration (median, range) | 96 (95 - 97) | |
| Radiological evidence of pneumonia (chest X-ray or CT) | 185 (49.5) | |
| Chest CT performed | 242 (64.7) | |
| Adverse reaction after regdanvimab infusion | 15 (4.0) | |
| Rash | 5 (1.3) | |
| Itching | 5 (1.3) | |
| Nausea/vomiting | 3 (0.8) | |
| Fever | 2 (0.5) | |
| Diarrhea | 1 (0.3) | |
| Use of additional therapeutic agents | 32 (8.6) | |
| Oxygen support during admission | 15 (4.0) | |
| Dexamethasone and other glucocorticoids | 28 (7.5) | |
| Remdesivir | 27 (7.2) | |
| Time from regdanvimab treatment to administration of additional therapeutic agents (days) | 5 (3 - 7) | |
| Outcome | ||
| Referral to tertiary care center for intensive care | 0 | |
| In-hospital mortality | 0 | |
Data are nos. (%) or medians (interquartile ranges) unless otherwise indicated.
aVaccination status was divided by vaccine administration before the date of symptom onset for symptomatic patients and by the date of diagnosis for asymptomatic patients. Patients were considered fully vaccinated at least 14 days after they received the second dose of ChAdOx1 nCoV-19 (Oxford/AstraZeneca, Cambridge, UK), BNT162b2 (Pfizer/BioNTech, New York, NY, USA and Mainz, Germany), or mRNA-1273 (Moderna, Cambridge, MA, USA); or at least 14 days after receipt of a single dose of Ad26.COV2.S (Janssen, Beerse, Belgium).
SpO2, peripheral oxygen saturation; CT, computed tomography.